torrent pharmaceuticals will host a conference call with investors and analysts on July 30, 2026, at 5:30 PM IST to review its financial performance for the quarter ended June 30, 2026. The meeting provides a platform for stakeholders to understand the company's operational results and strategic outlook for the period.

Conference Call Details

The teleconference will cover the financial outcomes of the first quarter of FY27. Investors can join the discussion using specific dial-in numbers provided for different regions.

International Access

International participants can connect via toll-free numbers designated for specific countries. The list includes access points for major markets such as the USA, UK, Japan, and Australia, among others.

Registration Information

Participants seeking 'Diamond Pass' access must register in advance using the specific link provided by the company. The registration process ensures streamlined entry into the conference call for eligible investors and analysts.

Torrent Pharmaceuticals is implementing a voluntary recall for select batches of Semalix injection disposable pens as a precautionary measure. This action follows a product recall notification issued by the manufacturer, Dr. Reddy's Laboratories Ltd., for a technical evaluation. The company emphasized that patient safety is of paramount importance and stated there is no risk to patients already on this treatment due to the recall.

The recall specifically targets Semalix Injection pens in 2 mg and 4 mg dosages that were manufactured by Dr. Reddy's Laboratories Ltd. Torrent Pharmaceuticals clarified that all other Stock Keeping Units (SKUs) of Semaglutide sold by the company remain completely unaffected. This includes oral formulations and other variants produced by different manufacturers.

Affected and Unaffected Products

The company provided a detailed breakdown of the product lines to clarify which items are subject to the recall and which remain available for use. The distinction is based on the specific product type and the manufacturing partner.

Patients or family members currently using any of the listed products have been advised to reach out to pv@torrentpharma.com for further clarification. The company confirmed that the recall is limited to the specific batches mentioned and does not extend to the broader product portfolio.